Edition:
United States

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

93.61USD
12:57pm EDT
Change (% chg)

$-0.43 (-0.46%)
Prev Close
$94.04
Open
$94.33
Day's High
$94.37
Day's Low
$93.45
Volume
215,264
Avg. Vol
393,254
52-wk High
$96.31
52-wk Low
$74.97

Latest Key Developments (Source: Significant Developments)

Novartis CEO Says U.S. Gov't Policy Environment Very Fluid
Thursday, 18 Jul 2019 09:01am EDT 

July 18 (Reuters) - Novartis AG ::NOVARTIS CEO SAYS PLANS TO INITIATE DISCUSSIONS WITH FDA OVER INTRATHECAL ADMINISTRATION OF ZOLGENSMA LATER THIS YEAR.NOVARTIS CFO SAYS PROFITABILITY BENEFITED IN H1 FROM VALSARTAN SUPPLY SHORTAGE.NOVARTIS CEO SAYS U.S. GOVERNMENT POLICY ENVIRONMENT "VERY FLUID" REGARDING DRUG PRICING AFTER TRUMP ADMINISTRATION DROPS REBATE RULE.NOVARTIS DRUG DIVISION CHIEF SAYS CONFIDENT ABOUT MS DRUG MAYZENT'S LONGTERM POTENTIAL, BUT SAYS 'THIS YEAR IS ALL ABOUT EDUCATION" AND IDENTIFYING PATIENTS.  Full Article

Novartis CEO Expects Q4 European Commission Approval For Zolgensma
Thursday, 18 Jul 2019 09:00am EDT 

July 18 (Reuters) - Novartis AG ::NOVARTIS CEO SAYS EXPECTS Q4 EUROPEAN COMMISSION APPROVAL FOR ZOLGENSMA.  Full Article

Lifemax Laboratories Says FDA Granted Rare Pediatric Disease Designation To Lm-030
Thursday, 18 Jul 2019 07:00am EDT 

July 18 (Reuters) - Novartis AG ::LIFEMAX LABORATORIES - FDA GRANTED RARE PEDIATRIC DISEASE DESIGNATION TO LM-030, AN INVESTIGATIONAL THERAPY LICENSED FROM NOVARTIS.  Full Article

Recordati To Acquire Worldwide Rights To Signifor And Osilodrostat (LCI699)
Friday, 12 Jul 2019 02:30pm EDT 

July 12 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA ::RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699).RECORDATI - ANNOUNCES SIGNING OF AN AGREEMENT WITH NOVARTIS FOR ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR AND SIGNIFOR LAR.RECORDATI - AGREEMENT ALSO COVERS ACQUISITION OF WORLDWIDE RIGHTS TO OSILODROSTAT (LCI699).RECORDATI - UPON COMPLETION OF TRANSACTION A CONSIDERATION OF $390 MILLION WILL BE DUE TO NOVARTIS.RECORDATI - UNDER TERMS OF AGREEMENT NOVARTIS WILL SUPPLY SIGNIFOR AND OSILODROSTAT (LCI699) PRODUCTS TO RECORDATI FOR A TRANSITIONAL PERIOD.  Full Article

Amphastar Pharmaceuticals Announces Settlement In Litigation With Momenta And Sandoz
Wednesday, 19 Jun 2019 06:00am EDT 

June 19 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS, INC. ANNOUNCES SETTLEMENT IN LITIGATION WITH MOMENTA AND SANDOZ.AMPHASTAR PHARMACEUTICALS - MOMENTA/SANDOZ WILL PAY CO $59.9 MILLION NO LATER THAN JULY 2.AMPHASTAR PHARMACEUTICALS INC - CO, MOMENTA/SANDOZ WILL SUBMIT STIPULATIONS OF DISMISSAL OF ALL PENDING LITIGATION BETWEEN PARTIES..  Full Article

Atara Biotherapeutics Appoints Pascal Touchon As Chief Executive Officer
Tuesday, 28 May 2019 05:00pm EDT 

May 28 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS APPOINTS PASCAL TOUCHON PRESIDENT, CHIEF EXECUTIVE OFFICER AND MEMBER OF THE BOARD OF DIRECTORS.ATARA BIOTHERAPEUTICS INC - TOUCHON WAS MOST RECENTLY AT NOVARTIS ONCOLOGY AS GLOBAL HEAD, CELL & GENE AND MEMBER OF ONCOLOGY EXECUTIVE COMMITTEE.ATARA BIOTHERAPEUTICS INC - ISAAC CIECHANOVER STEPPED DOWN FROM HIS ROLE AS PRESIDENT, CHIEF EXECUTIVE OFFICER.ATARA BIOTHERAPEUTICS INC - DIETMAR BERGER, ATARA'S GLOBAL HEAD OF RESEARCH AND DEVELOPMENT, HAS RESIGNED.  Full Article

FDA Approves Jakafi For The Treatment Of Patients With Acute Graft-Versus-Host Disease
Friday, 24 May 2019 01:43pm EDT 

May 24 (Reuters) - Incyte Corp ::FDA APPROVES JAKAFI® (RUXOLITINIB) FOR THE TREATMENT OF PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE.INCYTE CORP - JAKAFI WILL BE MADE AVAILABLE TO APPROPRIATE PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD IMMEDIATELY..INCYTE CORP - FDA APPROVED JAKAFI (RUXOLITINIB) FOR TREATMENT OF STEROID-REFRACTORY ACUTE GVHD IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER.  Full Article

Regenxbio Announces First FDA Approval Of A Gene Therapy Based On Its Proprietary Nav Technology Platform
Friday, 24 May 2019 01:14pm EDT 

May 24 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES FIRST FDA APPROVAL OF A GENE THERAPY BASED ON ITS PROPRIETARY NAV® TECHNOLOGY PLATFORM.REGENXBIO INC - ADDITIONAL APPROVALS FOR GENE THERAPY BASED ON ITS PROPRIETARY NAV® TECHNOLOGY PLATFORM ANTICIPATED IN EUROPE AND JAPAN IN 2019.  Full Article

Avexis Receives FDA Approval For Zolgensma, First And Only Gene Therapy For Pediatric Patients With Spinal Muscular Atrophy
Friday, 24 May 2019 12:31pm EDT 

May 24 (Reuters) - Novartis AG ::AVEXIS RECEIVES FDA APPROVAL FOR ZOLGENSMA®, THE FIRST AND ONLY GENE THERAPY FOR PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA).AVEXIS - ZOLGENSMA WILL BE MADE AVAILABLE IN THE U.S. AND WILL BE MARKETED BY AVEXIS, A NOVARTIS COMPANY.AVEXIS - ZOLGENSMA HAS PRIME (PRIORITY MEDICINES) DESIGNATION IN EUROPE, AND IS BEING REVIEWED UNDER ACCELERATED ASSESSMENT PROCEDURE.  Full Article

Sosei Heptares Says Marketing Application For Asthma Therapy Has Been Filed With EMA
Thursday, 23 May 2019 07:48pm EDT 

May 24 (Reuters) - Sosei Group Corp <4565.T>::SOSEI HEPTARES NOTES THAT A VALID MARKETING AUTHORIZATION APPLICATION FOR QVM149, A POTENTIAL NEW INHALED COMBINATION THERAPY FOR ASTHMA, HAS BEEN FILED WITH EUROPEAN MEDICINES AGENCY.MAA FILING HAS TRIGGERED A $2.5 MILLION PAYMENT TO SOSEI HEPTARES FROM NOVARTIS.  Full Article

BRIEF-Gilead Sciences Licenses Respiratory, Herpes Antiviral Research Programs From Novartis

* GILEAD SCIENCES LICENSES RESPIRATORY AND HERPES ANTIVIRAL RESEARCH PROGRAMS FROM NOVARTIS